These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
488 related articles for article (PubMed ID: 16169724)
21. Design, synthesis, and structure-activity relationships of a novel series of 5-alkylidenepyridazin-3(2H)-ones with a non-cAMP-based antiplatelet activity. Coelho A; Raviña E; Fraiz N; Yáñez M; Laguna R; Cano E; Sotelo E J Med Chem; 2007 Dec; 50(26):6476-84. PubMed ID: 18031002 [TBL] [Abstract][Full Text] [Related]
22. Synthesis and antiplatelet activity of new imidazole-4-carboxylic acid derivatives. Rehse K; Steege J Arch Pharm (Weinheim); 2005 Nov; 338(11):539-47. PubMed ID: 16281307 [TBL] [Abstract][Full Text] [Related]
23. Synthesis of N6-alkyl(aryl)-2-alkyl(aryl)thioadenosines as antiplatelet agents. Liu G; Xu J; Chen N; Zhang S; Ding Z; Du H Eur J Med Chem; 2012 Jul; 53():114-23. PubMed ID: 22531380 [TBL] [Abstract][Full Text] [Related]
24. [Synthesis and platelet aggregation inhibitory activity of 6-substituted dihydropyridazinones]. Yao FM; Sun CS Yao Xue Xue Bao; 1993; 28(7):548-52. PubMed ID: 8285059 [TBL] [Abstract][Full Text] [Related]
25. Novel furfurylidene N-acylhydrazones derived from natural safrole: discovery of LASSBio-1215, a new potent antiplatelet prototype. Rodrigues AP; Costa LM; Santos BL; Maia RC; Miranda AL; Barreiro EJ; Fraga CA J Enzyme Inhib Med Chem; 2012 Feb; 27(1):101-9. PubMed ID: 21612374 [TBL] [Abstract][Full Text] [Related]
26. Antiplatelet activity of carnosol is mediated by the inhibition of TXA2 receptor and cytosolic calcium mobilization. Lee JJ; Jin YR; Lim Y; Hong JT; Kim TJ; Chung JH; Yun YP Vascul Pharmacol; 2006 Sep; 45(3):148-53. PubMed ID: 16916624 [TBL] [Abstract][Full Text] [Related]
27. A comparative optical aggregometry study of antiplatelet activity of taxanes from Taxus cuspidata. Kim SY; Yun-Choi HS Thromb Res; 2010 Jun; 125(6):e281-4. PubMed ID: 20170941 [TBL] [Abstract][Full Text] [Related]
28. An antithrombotic agent, NQ301, inhibits thromboxane A2 receptor and synthase activity in rabbit platelets. Jin YR; Cho MR; Lee KS; Lee JJ; Lim Y; Han XH; Oh KW; Hong JT; Yoo HS; Yun YP Basic Clin Pharmacol Toxicol; 2005 Sep; 97(3):162-7. PubMed ID: 16128910 [TBL] [Abstract][Full Text] [Related]
29. Synthesis and platelet aggregation inhibitory effects of N-[(1H-pyrazol-1-yl)alkyl]benzoylamides. Ferroni R; Milani L; Simoni D; Orlandini P; Bottura M; Bardi A; Guarneri M Arzneimittelforschung; 1990 Jun; 40(6):705-9. PubMed ID: 2397007 [TBL] [Abstract][Full Text] [Related]
30. Synthesis, antiplatelet and in silico evaluations of novel N-substituted-phenylamino-5-methyl-1H-1,2,3-triazole-4-carbohydrazides. Jordão AK; Ferreira VF; Lima ES; de Souza MC; Carlos EC; Castro HC; Geraldo RB; Rodrigues CR; Almeida MC; Cunha AC Bioorg Med Chem; 2009 May; 17(10):3713-9. PubMed ID: 19380229 [TBL] [Abstract][Full Text] [Related]
31. New platelet aggregation inhibitors based on pyridazinone moiety. Costas T; Costas-Lago MC; Vila N; Besada P; Cano E; Terán C Eur J Med Chem; 2015 Apr; 94():113-22. PubMed ID: 25757094 [TBL] [Abstract][Full Text] [Related]
32. New pyrimido[5,4-c]cinnolines with antiplatelet activities. Rehse K; Gonska H Arch Pharm (Weinheim); 2005 Dec; 338(12):590-7. PubMed ID: 16281308 [TBL] [Abstract][Full Text] [Related]
33. Novel arylpyrazino[2,3-c][1,2,6]thiadiazine 2,2-dioxides as platelet aggregation inhibitors. 2. Optimization by quantitative structure-activity relationships. Campillo N; Goya P; Páez JA J Med Chem; 1999 Aug; 42(17):3279-88. PubMed ID: 10464014 [TBL] [Abstract][Full Text] [Related]
34. Pyran derivatives XIX. (Dialkylamino) substituted 1-benzopyranones and naphthopyranones with platelet antiaggregating activity. Di Braccio M; Roma G; Leoncini G; Poggi M Farmaco; 1995 Oct; 50(10):703-11. PubMed ID: 8590578 [TBL] [Abstract][Full Text] [Related]
35. 2'-Ethoxy-5'-methoxy-2-(5-methylthienyl)chalcone inhibits collagen-induced protein tyrosine phosphorylation and thromboxane formation during platelet aggregation and adhesion. Lo HM; Huang TF; Lin CN; Peng HC; Wu WB Pharmacology; 2009; 84(3):145-52. PubMed ID: 19690443 [TBL] [Abstract][Full Text] [Related]
36. Design, synthesis of novel tryptophan derivatives for antiplatelet aggregation activity based on tripeptide pENW (pGlu-Asn-Trp). Xie Z; Feng S; Wang Y; Cao C; Huang J; Chen Y; Kong Y; Li Z Eur J Med Chem; 2015 Sep; 102():363-74. PubMed ID: 26298494 [TBL] [Abstract][Full Text] [Related]
37. Antiplatelet activity of beta-carboline alkaloids from Perganum harmala: a possible mechanism through inhibiting PLCgamma2 phosphorylation. Im JH; Jin YR; Lee JJ; Yu JY; Han XH; Im SH; Hong JT; Yoo HS; Pyo MY; Yun YP Vascul Pharmacol; 2009; 50(5-6):147-52. PubMed ID: 19073282 [TBL] [Abstract][Full Text] [Related]
38. Design, synthesis, and structure-activity relationship studies of novel 1-[(1-acyl-4-piperidyl)methyl]-1H-2- methylimidazo[4,5-c]pyridine derivatives as potent, orally active platelet-activating factor antagonists. Carceller E; Merlos M; Giral M; Balsa D; García-Rafanell J; Forn J J Med Chem; 1996 Jan; 39(2):487-93. PubMed ID: 8558517 [TBL] [Abstract][Full Text] [Related]
39. The synthesis and biologic evaluation of anti-platelet and cytotoxic β-nitrostyrenes. Hsieh PW; Chang YT; Chuang WY; Shih HC; Chiang SZ; Wu CC Bioorg Med Chem; 2010 Nov; 18(21):7621-7. PubMed ID: 20850977 [TBL] [Abstract][Full Text] [Related]
40. New 1H-pyrazole-4-carboxamides with antiplatelet activity. Rehse K; Kotthaus J; Khadembashi L Arch Pharm (Weinheim); 2009 Jan; 342(1):27-33. PubMed ID: 19051198 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]